Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q99797
UPID:
MIPEP_HUMAN
Alternative names:
-
Alternative UPACC:
Q99797; Q5JV15; Q5T9Q9; Q96G65
Background:
The Mitochondrial intermediate peptidase, encoded by the gene with accession number Q99797, plays a crucial role in mitochondrial function by cleaving proteins to their mature sizes after they are imported into the mitochondrion. This process is vital for maintaining mitochondrial integrity and functionality.
Therapeutic significance:
The protein is linked to Combined oxidative phosphorylation deficiency 31, a severe mitochondrial disease manifesting in early infancy with symptoms like developmental delays, seizures, and early childhood mortality. Understanding the role of Mitochondrial intermediate peptidase could open doors to potential therapeutic strategies for this debilitating condition.